The Journal of Pediatrics
Volume 150, Issue 1 , Pages 72-76 , January 2007

Takayasu Arteritis in Children: Preliminary Experience with Cyclophosphamide Induction and Corticosteroids Followed by Methotrexate

Received 14 March 2006 ,Revised 1 June 2006 ,Accepted 12 October 2006.

References 

  1. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med. 1994;120:919–929
  2. Liang P, Hoffman GS. Advances in medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol. 2004;17:16–24
  3. Lindsley CB, Laxer RM. Granulomatous vasculitis, giant cell arteritis, and sarcoidosis. In:  Cassidy JT,  Petty RE,  Laxer RM,  Lindsley CB editor. Textbook of Pediatric Rheumatology. 5th edition. Philadelphia: Elsevier Saunders; 2005;p. 539–560
  4. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33:1129–1134
  5. Ozen S, Ruperto N, Dillon M, Bagga A, Barron K, Davin JC, et al. EULAR/PRES Endorsed Consensus Criteria for the Classification of Childhood Vasculitides. Ann Rheum Dis. 2006;65:936–941
  6. Duzova A, Turkmen O, Cinar A, Cekirge S, Saatci U, Ozen S. Takayasu’s arteritis and tuberculosis: a case report. Clin Rheumatol. 2000;19:486–489
  7. Vanoli M, Daina E, Salvarani C, Sabbadini MG, Rossi C, Bacchiani G Itaka Study Group. Takayasu’s arteritis: a study of 104 Italian patients. Arthritis Rheum. 2005;53:100–107
  8. Koening CL, Langford CA. Novel therapeutic strategies for large vessel vasculitis. Rheum Dis Clin North Am. 2006;32:173–186
  9. Latta K, von Schnakenburg C, Ehrich JHH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatric Nephrology. 2001;16:271–282
  10. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener’s granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. 1992;35:1322–1329
  11. Liang GC, Madayag M. Multiple percutaneous transluminal angioplasties and low dose methotrexate for Takayasu’s arteritis. J Rheumatol. 1989;16:1370–1373
  12. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum. 1994;37:578–582
  13. Besson-Leaud L, Grenier N, Besson-Leaud M, Boniface C, Guillard JM. Takayasu’s disease: interest in methotrexate treatment. Arch Pediatr. 2001;8:724–727
  14. Shetty AK, Stopa AR, Gedalia A. Low-dose methotrexate as a steroid-sparing agent in a child with Takayasu’s arteritis. Clin Exp Rheumatol. 1998;16:335–336
  15. Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu’s arteritis. J Rheumatol. 2003;30:1793–1798
  16. Daina E, Schieppati A, Remuzzi G. Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med. 1999;130:422–426
  17. Hoffman GS, Merkel PA, Brasington , Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004;50:2296–2304
  18. Tato F, Rieger J, Hoffmann U. Refractory Takayasu’s arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol. 2005;24:304–307
  19. Kodama K, Kida O, Morotomi Y, Tanaka K. Male siblings with Takayasu’s arteritis suggest genetic etiology. Heart Vessels. 1986;2:51–54

PII: S0022-3476(06)01018-3

doi: 10.1016/j.jpeds.2006.10.059

The Journal of Pediatrics
Volume 150, Issue 1 , Pages 72-76 , January 2007

Article Tools